This study aims to determine whether treatment of CMV positive (CMV+) individuals with major
depressive disorder (MDD) with valganciclovir (VGCV) alters neural circuitry, reduces
inflammation, and improves depressive behavior and symptoms to a greater extent than placebo.
In this double-blind, randomized placebo-controlled, parallel group trial, 24 individuals
with a Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) scale score ≥ 14
will be enrolled to participate in an 8-week treatment study. Participants will be randomized
with a 1-1 ratio to receive 900 milligrams (mg) VGCV or placebo to be taken orally once per
day. Participants will complete a 2-hour pre-screen, a baseline blood-draw, clinical
evaluation, and MRI scan (visit 2), a clinical evaluation, blood draw, and MRI scan at week 4
(visit 6), and a clinical evaluation, blood draw, and MRI scan at week 8 (visit 10). Weekly
telephonic visits to assess depressive symptoms and side effects will held between the
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.